These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20397869)

  • 1. "Everyone deserves services no matter what": defining success in harm-reduction-based substance user treatment.
    Lee HS; Zerai A
    Subst Use Misuse; 2010 Dec; 45(14):2411-27. PubMed ID: 20397869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving health and social care relationships for harm reduction.
    Allman D; Myers T; Schellenberg J; Strike C; Cockerill R; Cavalieri W
    Int J Drug Policy; 2007 May; 18(3):194-203. PubMed ID: 17689366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Principles of harm reduction. Harm Reduction Coalition.
    Newsline People AIDS Coalit N Y; 1998 Jun; ():7-8. PubMed ID: 11367472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High and low threshold service provision in drug-free settings: Practitioner views.
    Eversman MH
    Int J Drug Policy; 2010 Nov; 21(6):501-6. PubMed ID: 20395121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Issues in subject recruitment and retention with pregnant and parenting substance-abusing women.
    Howard J; Beckwith L
    NIDA Res Monogr; 1996; 166():68-86. PubMed ID: 8818166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. State of the art in harm reduction psychotherapy: an emerging treatment for substance misuse.
    Tatarsky A; Marlatt GA
    J Clin Psychol; 2010 Feb; 66(2):117-22. PubMed ID: 20049922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harm reduction among at-risk elderly drinkers: a site-specific analysis from the multi-site Primary Care Research in Substance Abuse and Mental Health for Elderly (PRISM-E) study.
    Lee HS; Mericle AA; Ayalon L; Areán PA
    Int J Geriatr Psychiatry; 2009 Jan; 24(1):54-60. PubMed ID: 18613283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partners in treatment: relational psychoanalysis and harm reduction therapy.
    Rothschild D
    J Clin Psychol; 2010 Feb; 66(2):136-49. PubMed ID: 20049924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do specialized services exist for LGBT individuals seeking treatment for substance misuse? A study of available treatment programs.
    Cochran BN; Peavy KM; Robohm JS
    Subst Use Misuse; 2007; 42(1):161-76. PubMed ID: 17366131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substance use disorder treatment programs in Switzerland and the USA: Program characteristics and 1-year outcomes.
    Moggi F; Giovanoli A; Strik W; Moos BS; Moos RH
    Drug Alcohol Depend; 2007 Jan; 86(1):75-83. PubMed ID: 16782286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injecting risk behaviour and related harm among men who use performance- and image-enhancing drugs.
    Larance B; Degenhardt L; Copeland J; Dillon P
    Drug Alcohol Rev; 2008 Nov; 27(6):679-86. PubMed ID: 18825549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing the harm of "harm reduction".
    Beirness DJ; Notarandrea R; Jesseman R; Perron M
    Clin Pharmacol Ther; 2008 Apr; 83(4):523-5. PubMed ID: 18349874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between substance user treatment and 12-step fellowships: current knowledge and research questions.
    Magura S
    Subst Use Misuse; 2007; 42(2-3):343-60. PubMed ID: 17558934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strengthening drug policy and practice through ethics engagement: an old challenge for a new harm reduction.
    Irwin KS; Fry CL
    Int J Drug Policy; 2007 Mar; 18(2):75-83. PubMed ID: 17689348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Making the case for harm reduction. A provider organization cites the success of harm reduction efforts in Vancouver, British Columbia.
    Bayes S
    Behav Healthc; 2007 Jul; 27(7):43-4. PubMed ID: 18027621
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term follow-up of people with co-existing psychiatric and substance use disorders: patterns of use and outcomes.
    Greig RL; Baker A; Lewin TJ; Webster RA; Carr VJ
    Drug Alcohol Rev; 2006 May; 25(3):249-58. PubMed ID: 16753649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. End-of-treatment outcomes in cognitive-behavioral treatment and 12-step substance use treatment programs: do they differ and do they predict 1-year outcomes?
    Johnson JE; Finney JW; Moos RH
    J Subst Abuse Treat; 2006 Jul; 31(1):41-50. PubMed ID: 16814009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: a national drug abuse treatment clinical trials network study.
    Petry NM; Peirce JM; Stitzer ML; Blaine J; Roll JM; Cohen A; Obert J; Killeen T; Saladin ME; Cowell M; Kirby KC; Sterling R; Royer-Malvestuto C; Hamilton J; Booth RE; Macdonald M; Liebert M; Rader L; Burns R; DiMaria J; Copersino M; Stabile PQ; Kolodner K; Li R
    Arch Gen Psychiatry; 2005 Oct; 62(10):1148-56. PubMed ID: 16203960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National Drug Abuse Treatment Clinical Trials Network study.
    Peirce JM; Petry NM; Stitzer ML; Blaine J; Kellogg S; Satterfield F; Schwartz M; Krasnansky J; Pencer E; Silva-Vazquez L; Kirby KC; Royer-Malvestuto C; Roll JM; Cohen A; Copersino ML; Kolodner K; Li R
    Arch Gen Psychiatry; 2006 Feb; 63(2):201-8. PubMed ID: 16461864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal timing of use reduction vs. harm reduction in a drug epidemic model.
    Caulkins JP; Tragler G; Wallner D
    Int J Drug Policy; 2009 Nov; 20(6):480-7. PubMed ID: 19361975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.